logo

For the Inventor, By the Inventor

Yokohama, Japan

Shin-ichiro Fujii

USPTO Granted Patents = 7

Average Co-Inventor Count = 2.1

ph-index = 3

Forward Citations = 13(Granted Patents)


Location History:

  • Kanagawa, JP (2015)
  • Wako, JP (2019)
  • Yokohama, JP (2017 - 2021)
  • Saitama, JP (2023)

Company Filing History:

goldMedal7 out of 856 
 
Riken Corporation
 patents

Years Active: 2015-2023

Loading Chart...
7 patents (USPTO):Explore Patents
1. 11834674 - Modified immunocyte, method for producing modified immunocyte and utilization thereof (2023-12-05),
2. 11072802 - Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product (2021-07-27),
3. 10813950 - Immunotherapy using allo-NKT cells, cells for immunotherapy in which alpha chain of t-cell receptor (TCR) gene has been rearranged to uniform Vα-Jα, and banking of NKT cells derived from said cells (2020-10-27),
4. 10416160 - Memory invariant NKT cell marker (2019-09-17),
5. 10316332 - Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product (2019-06-11),
6. 9783821 - Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct (2017-10-10),
7. 8945922 - Generating a mature NKT cell from a reprogrammed somatic cell with a T-cell antigen receptor α-chain region rearranged to uniform Va-Ja in a NKT-cell specific way (2015-02-03),

Title: **Innovative Contributions of Shin-ichiro Fujii in Immunotherapy**

Introduction:

Shin-ichiro Fujii, an accomplished inventor based in Yokohama, Japan, has made significant strides in the field of immunotherapy through his groundbreaking patented technologies. With a total of seven patents to his name, Fujii’s work focuses on modifying immunocytes to improve immune responses, showcasing his dedication to advancing medical science.

Latest Patents:

Among his most notable inventions are two recent patents that stand out for their innovative approaches. The first patent relates to a modified immunocyte, which is capable of expressing exogenous unmodified T cell receptor α-chain and β-chain on its surface. This modified immunocyte offers a new mechanism to appropriately induce immunity in vivo, representing a potential leap forward in therapeutic approaches to immune-related diseases.

The second patent involves a cell for immunotherapy that is designed to include a nucleic acid encoding a Wilms tumor 1 gene product. This innovative cell is instrumental in targeting specific tumor antigens, thereby enhancing the efficacy of immunotherapeutic approaches. These patents not only highlight Fujii’s ingenuity but also provide promising avenues for future cancer treatments.

Career Highlights:

Shin-ichiro Fujii is associated with RIKEN Corporation, a leading research institution renowned for its advances in scientific research and innovation. His tenure at RIKEN reflects his commitment to pioneering research in the biomedical field, where he continues to push the boundaries of immunological treatments.

Collaborations:

Throughout his career, Fujii has collaborated with notable colleagues, including Kanako Shimizu and Jun Shinga. These partnerships have fostered a collaborative environment that enhances creative problem-solving and accelerates the journey from invention to practical application.

Conclusion:

Shin-ichiro Fujii stands as a testament to the power of innovation in the field of immunotherapy. His patents reflect not only his expertise but also his unwavering commitment to improving healthcare solutions through cutting-edge inventions. As the landscape of medical treatment continues to evolve, Fujii’s contributions promise to leave an indelible mark on the future of immunotherapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…